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ABSTRACT
Molecular medicine has entered a high-tech age that provides curative treatments of complex
genetic diseases through genetically engineered cellular medicinal products. Their clinical imple-
mentation requires the ability to stably integrate genetic information through gene transfer vec-
tors in a safe, effective and economically viable manner. The latest generation of Sleeping Beauty
(SB) transposon vectors fulfills these requirements, and may overcome limitations associated with
viral gene transfer vectors and transient non-viral gene delivery approaches that are prevalent in
ongoing pre-clinical and translational research. The SB system enables high-level stable gene
transfer and sustained transgene expression in multiple primary human somatic cell types,
thereby representing a highly attractive gene transfer strategy for clinical use. Here we review
several recent refinements of the system, including the development of optimized transposons
and hyperactive SB variants, the vectorization of transposase and transposon as mRNA and DNA
minicircles (MCs) to enhance performance and facilitate vector production, as well as a detailed
understanding of SB’s genomic integration and biosafety features. This review also provides a
perspective on the regulatory framework for clinical trials of gene delivery with SB, and illustrates
the path to successful clinical implementation by using, as examples, gene therapy for age-
related macular degeneration (AMD) and the engineering of chimeric antigen receptor (CAR)-
modified T cells in cancer immunotherapy.
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Introduction: vectors in gene therapy and
genetic engineering
The ability to deliver natural or synthetic genes into
human somatic cell types provides the technological
basis for gene therapy to treat inherited and acquired
genetic diseases, and enables genetic engineering of
cellular medicinal products that are endowed with
novel properties and functions for use as diagnostic
and therapeutic tools in medicine. The vast majority
(70%) of gene delivery systems used in ongoing clin-
ical trials of gene therapy are based on viral vectors,
and only a small proportion of trials utilizes non-viral
delivery systems, mainly non-integrating naked plasmid
DNA, that only provide transient gene expression (Gene
Therapy Clinical Trials Worldwide, http://www.abedia.
com/wiley/vectors.php (Figure 1( A,B)).
This article will focus on non-viral stable gene trans-
fer through the Sleeping Beauty (SB) transposon as a
viable and ready-to-use alternative to viral gene transfer
vectors. We will review basic principles, and feature the
key scientific and technologic advances that have been
made to position SB transposition as a preferred gene
delivery system in translational and clinical medicine.
The conceptual appeal of SB transposition for gene
delivery is illustrated by examples of clinical applica-
tions in gene therapy and genetic engineering, and
complemented by a concise review of regulatory
aspects for clinical implementation.
Viral gene transfer vectors
Viral vector systems are attractive for gene delivery,
because viruses have evolved the ability to cross
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through cellular membranes by infection, thereby deliv-
ering nucleic acids to target cells. However, some viral
vectors, including those derived from adenoviruses or
adeno-associated viruses (AAVs), are not equipped for
chromosomal integration, and thus remain largely epi-
somal. Especially in cycling cells, episomal DNA is grad-
ually lost requiring re-administration in vivo in order to
sustain a desired level of transgene expression over
time. However, repeated delivery can provoke immune
responses against vector-encoded proteins [reviewed in
(Hartman et al., 2008)], which can manifest as loss of
the desired therapeutic effect and potentially therapy-
related adverse events. In contrast, retroviral vectors
integrate their therapeutic cargo into the genome, and
thus have the potential to confer long-term transgene
expression. Indeed, hematopoietic stem cell (HSC)-
based gene therapy with integrating viral vectors has
clearly provided therapeutic benefit in primary immu-
nodeficiencies (including SCID-X1, ADA-SCID), thalas-
semia and leukodystrophies (Aiuti et al., 2013a; Biffi
et al., 2013; Cartier et al., 2009; Cavazzana-Calvo et al.,
2010). A concern with retroviral vectors is that chromo-
somal integration may be associated with genotoxicity
and mutagenic effects elicited by insertion of the vector
into or near proto-oncogenes (Baum et al., 2004;
Deichmann et al., 2007; Hacein-Bey-Abina et al., 2003;
Hacein-Bey-Abina et al., 2008; Kustikova et al., 2005).
Such risk is especially pronounced with gammaretroviral
vectors based on the murine leukemia virus (MLV) that
preferentially integrate into transcriptional regulatory
Figure 1. Viral and non-viral vectors in currently running gene therapy clinical trials. A) Percent contribution of different vector
systems of currently running clinical trials. B) List of some of the most popular vector systems employed in clinical trials. The list
also contains the currently running trials with the Sleeping Beauty transposon (see colour version of this figure at www.tandfon-
line.com/ibmg).
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elements of active genes (Cattoglio et al., 2010; Cavazza
et al., 2013; De Ravin et al., 2014); in fact, severe adverse
events associated with vector integration have been
observed in clinical trials for SCID-X1 (Hacein-Bey-Abina
et al., 2003; Hacein-Bey-Abina et al., 2008; Howe et al.,
2008; Thrasher et al., 2006), X-CGD (Ott et al., 2006) and
WAS (Braun et al., 2014).
Furthermore, HIV-derived lentiviral vectors are poten-
tial mutagens due to their biased insertion into tran-
scription units (Cavazza et al., 2013). Although lentiviral
vectors appear to be safer than gammaretroviral vectors
in gene therapy, recent studies indicate that some HIV
integrations into genes associated with cancer or cell
cycle regulation may confer a survival advantage of
HIV-infected cells, and thus a clonal imbalance of HIV
integrations in AIDS patients (Maldarelli et al., 2014;
Wagner et al., 2014). A potential technical hurdle that
can set limitations to vector design for clinical use of
retroviral vectors is that large transgenes may inhibit
viral reverse transcription and packaging. Finally, the
high costs associated with manufacture of clinical-grade
retroviral vector batches seem incompatible with their
use as gene delivery systems in large patient cohorts in
routine medical practice.
As a result, significant efforts have been made to
craft novel gene transfer vectors that exceed the
qualities of currently available viral vectors in: i) effi-
cacy: i.e. achieve high-level stable gene transfer at
low toxicity to the host cell; ii) safety: i.e. induce low
levels of genotoxicity and possess a “safe” integra-
tion profile, with a high proportion of integrations
into genomic safe harbors (GSHs); iii) economic via-
bility: i.e. are associated with acceptable cost per
treatment, and scalable/exportable vector production
to serve large numbers of patients.
Non-viral gene transfer vectors
Non-viral vector systems, including nucleic acid vectors
such as plasmid DNA, generally suffer from inefficient
cellular delivery, pronounced cellular toxicity and lim-
ited duration of transgene expression due to the lack of
genomic insertion and resulting degradation and/or
dilution of the vector in transfected cell populations.
Recent developments of non-viral delivery techniques,
including liposomal formulations, nanoparticles,
advanced electroporation methods such as nucleofec-
tion and cell-penetrating peptides can significantly
enhance transfer of nucleic acids into therapeutically
relevant cell types. However, just like non-integrating
viral systems, non-viral vectors do not provide long-
term nuclear maintenance and transgene expression in
dividing cell types such as stem cells. One class of non-
viral vector system that unites favorable characteristics
of integrating viral vectors (i.e. stable chromosomal
integration and long-lasting transgene expression) with
those of non-viral delivery systems (i.e. lower immuno-
genicity, enhanced safety profile and reduced costs of
GMP manufacture) is transposon-based gene delivery
systems.
Non-viral gene transfer using the Sleeping
Beauty transposon
Jumping genes: transposon basics
DNA transposons are genetic elements with the abil-
ity to change their positions within the genome. The
prevalent mode of transposition in the genome is
via a cut-and-paste mechanism. In nature, these ele-
ments exist as mobile (“jumping”) units of DNA con-
taining a transposase gene flanked by terminal
inverted repeats (TIRs) that carry transposase binding
sites (Figure 2(A)). Importantly, it is possible to separ-
ate the two functional components of the trans-
poson (the TIRs and the transposase) in the form of
bi-component vector systems. Transposon-based vec-
tors enable incorporation of virtually any DNA
sequence of interest between the transposon TIRs
and mobilization by trans-supplementing the transpo-
sase in the form of an expression plasmid (Figure
2(B)), very much like non-autonomous viral vectors
are produced in packaging cell lines. In the transpos-
ition process, the transposase enzyme mediates the
excision of the element from its donor plasmid, fol-
lowed by reintegration of the transposon into a
chromosomal locus (Figure 2(C)). This feature makes
transposons natural and easily controllable DNA
delivery vehicles that can be used as tools for versa-
tile applications in genetic engineering, including
gene therapy.
Discovery of the Sleeping Beauty transposon
Based on ancient, inactive transposon sequences iso-
lated from fish genomes, an active transposon was
reconstructed, and named SB after the Grimm brothers’
famous fairy tale, because it was literally awakened after
a long evolutionary “sleep” (Ivics et al., 1997). SB was
the first transposon ever shown capable of efficient
transposition in vertebrate cells, thereby enabling new
avenues for genetic engineering, including gene ther-
apy [reviewed in (Boehme et al., 2015; Hackett et al.,
2010; 2011; Ivics et al., 2009; Izsvak et al., 2010; Ivics &
Izsvak, 2010, 2011; Narayanavari et al., 2016;
Vandendriessche et al., 2009)].
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The advantage of SB transposon-based gene delivery
is that it combines the favorable features of viral vectors
with those of naked DNA molecules. Namely, owing to
permanent genomic insertion of transgene constructs
(Figure 2(C)), transposition-mediated gene delivery can
lead to sustained and efficient transgene expression in
preclinical animal models (Hackett et al., 2010).
However, in contrast to viral vectors, transposon vectors
can be maintained and propagated as plasmid DNA
(Figure 2), which makes them simple and inexpensive
to manufacture, an important consideration for imple-
mentation and scale-up in clinical practice. Further
advantages of SB as gene-transfer system compared to
viral vectors include its lower immunogenicity in vivo
(Yant et al., 2000), the greater capacity for genetic cargo
(Zayed et al., 2004) and its superior biosafety profile
(Ivics et al., 2007; Moldt et al., 2007; Vandendriessche
et al., 2009; Walisko et al., 2008). Because transposition
proceeds through a cut-and-paste mechanism that only
involves DNA, transposon vectors are not prone to
incorporating mutations by reverse transcription [that
are generated in retroviral stocks at reasonable frequen-
cies (Menendez-Arias, 2009)], and can tolerate larger
and more complex transgenes.
Performance facts of Sleeping Beauty
transposition
Cargo capacity
There is an inverse correlation between the size of the
SB transposon unit and the efficiency at which transpos-
ition takes place (Fischer et al., 1999; Izsvak et al., 2000;
Karsi et al., 2001; Lampe et al., 1998), and such effect
was also observed with the insect piggyBac (PB) trans-
poson (Wang et al., 2014) and with the bacterial trans-
posons IS1 (Chandler et al., 1982) and Tn10 (Morisato
et al., 1983). There are at least two molecular mecha-
nisms that can explain this phenomenon. First, in order
to form a catalytically primed transposon/transposase
complex (also called transpososome), the two ends of
the transposon must be held together in close physical
proximity by transposase molecules in a complex often
called a synaptic complex or a paired-end complex
(PEC) (Ivics & Izsvak, 2015). Formation of the PEC is a
strict requirement for transposon excision (Wang et al.,
2016b). It is conceivable that there might be a limitation
in PEC formation in case the transposon ends are far
apart, which can manifest in less efficient transposition
Figure 2. The Sleeping Beauty transposon system. A) Autonomous transposable elements consist of terminal inverted repeats
(LIR¼ left inverted repeat; RIR¼ right inverted repeat, black arrows) that flank the transposase gene (yellow). B) Bi-component,
trans-arrangement transposon vector system for delivering transgenes that are maintained in plasmids. One component contains
a gene of interest (green) between the transposon TIRs carried by a plasmid vector, whereas the other component is a transpo-
sase expression plasmid, in which the black arrow represents the promoter driving expression of the transposase. C) The trans-
poson carrying a gene of interest (GOI) is excised from the donor plasmid and is integrated at a chromosomal site by the
transposase. D) One-vector or cis-arrangement, in which the transposase expression cassette and the GOI are located on the same
plasmid. E) Plasmid-based transposon cassettes can be mobilized by transposase supplied as mRNA (see colour version of this fig-
ure at www.tandfonline.com/ibmg).
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of larger transposons. A strategy to partially rescue
transposition of large transgene constructs is to shorten
the length of DNA that connects the transposon ends
outside the transposon (Izsvak et al., 2000). In case of a
plasmid vector carrying the transposon unit, this means
shortening the plasmid backbone. By placing the trans-
poson TIRs next to one another, bacterial artificial chro-
mosomes (BACs) over 100 kb in length have been
demonstrated to transpose at reasonable efficiencies in
human ES cells (Rostovskaya et al., 2012; Rostovskaya
et al., 2013). The second mechanism limiting transpos-
ition of large constructs is a suicidal transpositional
mechanism called autointegration (Wang et al., 2014).
Autointegration means that following excision the
transposon ends attack a TA dinucleotide inside the
transposon, as opposed to a TA site in the target gen-
ome. This will abort the reaction and effectively kill the
transposing element. Since larger transposons contain
more potential target sites, they could be particularly
attractive targets for autointegration. Indeed, increasing
size was found to sensitize SB transposition for autoin-
tegration (Wang et al., 2014).
Although larger transposons are expected to trans-
pose less efficiently, there does not seem to exist an
absolute upper size limit for transposition, or at least
this limit has not been experimentally reached. This is
in sharp contrast to popular viral gene delivery systems,
where packaging into infectious viral particles sets a
strict limitation to the size of cargo to be incorporated.
Indeed, recombinant vectors based on AAV are not
competent to package vector genomes>5 kb (Hirsch
et al., 2016; Salganik et al., 2015), and both retroviral
and lentiviral vectors undergo a severe loss of titer
beyond a vector size of 8–10 kb (Matrai et al., 2010;
Sinn et al., 2005).
Transgene expression level and stability
Any transgene vector system should ideally provide
long-term expression of transgenes. By using classical,
plasmid-based, non-viral delivery approaches, expres-
sion from the extrachromosomal plasmid rapidly
declines following delivery. Transgenes delivered by
non-viral approaches often form long, repeated arrays
(concatemers) that are targets for transcriptional silenc-
ing by heterochromatin formation. In addition, long-
term expression of transgenes delivered by retroviruses
has been shown to be compromised by transcriptional
silencing (Jahner et al., 1982; Pannell & Ellis, 2001). It
was shown that the zinc finger protein ZFP809 bridges
the integrated proviral MLV genome and the tripartite
motif-containing 28 transcriptional co-repressor in
embryonic stem cells (Wolf & Goff, 2009). Thus,
sequence elements in the vector itself can predispose
the cargo for silencing. Cut-and-paste DNA transpos-
ition results in a single copy of the transgene per inser-
tion locus; thus, concatemer-induced gene silencing is
by definition a non-issue. Indeed, Grabundzija et al.
found that transposon insertions delivered by the SB
system only rarely (<2% of all insertions) undergo
silencing in HeLa cells (Grabundzija et al., 2010), indicat-
ing that it is unlikely that certain sequence motifs in the
transposon vector are recognized by mediators of
silencing in the cell.
An additional factor that may provoke transgene
silencing is the cargo DNA, particularly the type of pro-
moter used to drive expression of the gene of interest.
Indeed, it was previously shown that transgene con-
structs delivered into mouse cells using SB transposition
can be subject to epigenetic regulation by CpG methy-
lation. A determinant of epigenetic modifications of the
integrating transposon vector was found to be the
cargo transgene construct itself, with viral promoter ele-
ments playing a major role (Garrison et al., 2007).
However, with careful promoter choice, several studies
have established that SB-mediated transposition pro-
vides long-term expression in vivo. Notably, stable trans-
gene expression from SB vectors was seen in mice after
gene delivery in the liver (Aronovich et al., 2009; Kren
et al., 2009; Ohlfest et al., 2005b; Yant et al., 2000), lung
(Belur et al., 2003; Liu et al., 2004), brain (Ohlfest et al.,
2005a) and blood after hematopoietic reconstitution
in vivo (Mates et al., 2009; Xue et al., 2009). Thus, it
appears that SB transposon vectors have the capacity to
provide long-term expression of transgenes both
in vitro and in vivo.
Sleeping Beauty transposition in pre-clinical
models
In ex vivo gene delivery, the therapeutic gene vector is
introduced into a selected cell population that had
been isolated from a donor, and the genetically engi-
neered cells are transplanted into a patient. Depending
on whether the donor is the patient itself or another
person, we differentiate between autologous or allo-
geneic cell products, respectively. Unlike viruses, trans-
posons are not equipped to cross cell membranes
through infection. Thus, it is necessary to combine the
transposon vectors composed of naked nucleic acids
(DNA and mRNA) with technologies capable of efficient
delivery of these non-viral vectors into cells. Since the
efficiency of transposition is dependent on the effi-
ciency of uptake of the introduced nucleic acids into
the cell nuclei, delivery is a rate-limiting factor in trans-
position, and is thus of paramount importance. In
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principle, any technology developed for transferring
nucleic acids into cells can be combined with transposon
vectors. Unfortunately, there is no generally applicable
method, and procedures must be established for each
cell type. In hard-to-transfect cells, including primary
human cell types, delivery of transposon-based vectors
can be significantly facilitated by nucleofection, a pro-
cedure based on electroporation that transfers nucleic
acids directly into the nucleus. Indeed, nucleofection
facilitated transposition in CD34þ HSCs (Hollis et al.,
2006; Izsvak et al., 2009; Mates et al., 2009; Sumiyoshi
et al., 2009; Xue et al., 2009), primary T cells (Gogol-
Doring et al., 2016; Huang et al., 2008, 2010; Singh et al.,
2008) and human embryonic stem cells (Orban et al.,
2009; Wilber et al., 2007). Importantly, in the context of
the hematopoietic system, this ex vivo gene delivery pro-
cedure apparently did not compromise the potential of
transposon-marked CD34þ cells to differentiate normally
into the erythroid, megakaryocytic, granulocyte/mono-
cyte/macrophage (Mates et al., 2009) as well as into the
CD4þCD8þ T, CD19þ B, CD56þCD3 NK, and CD33þ
myeloid lineages (Xue et al., 2009). The robustness and
feasibility of this non-viral, transposon-based procedure
significantly facilitates clinical realization of ex vivo stem
cell therapy for the treatment of hematopoietic disorders
and cancer, and is already successfully applied in humans
(Kebriaei et al., 2016).
Refinement of Sleeping Beauty for clinical
applications
There were three major areas of development and
refinement of SB technology bearing paramount
importance for clinical translation: i) increasing gene
transfer rate and lowering toxicity; ii) defining suitable
vectors to encode transposase and transposon;
iii) establishing a biosafety profile that satisfied require-
ments for clinical use.
Enhancing Sleeping Beauty’s performance index
Hyperactive SB transposases
In evolutionary terms, the SB transposon was a successful
element with the ability of colonizing several fish
genomes millions of years ago (Ivics et al., 1996).
However, even successful transposons have not been
selected for the highest possible activity. On the contrary,
there is likely a strong selective pressure to avoid inser-
tional mutagenesis of essential genes of their host. In an
attempt to derive hyperactive transposase variants for
advanced genetic engineering, amino acid substitutions
spanning almost the entire SB transposase polypeptide
have been screened for eliciting a change in catalytic
activity. These amino acid replacements were conducted
either by systematic alanine-scanning (Wang et al.,
2016b; Yant et al., 2004), by “transplanting” single amino
acids or small (2–7 aa) blocks of amino acids from related
transposases (Baus et al., 2005; Geurts et al., 2003; Zayed
et al., 2004), and by replacement of selected amino acid
residues based on charge (Zayed et al., 2004). These
approaches generated transposase variants with i) no
change in activity; ii) reduced activity or iii) a relatively
modest increase of transposition activity. A second-gen-
eration SB transposase called SB11 contains five amino
acid replacements (selected based on a phylogenetic
comparison to active Tc1/mariner transposases) over the
first-generation transposase (Geurts et al., 2003). SB11 is
about 3-fold more active than the first-generation SB
transposase, and has been primarily employed in cur-
rently running clinical trials based on CAR-engineered T
cells (Kebriaei et al., 2016) (Figure 1(B)).
Surprisingly, some combinations of hyperactive
mutations were found to result in a significant reduc-
tion of activity. Nevertheless, screening of a library of
possible combinations yielded SB transposase variants
with significantly enhanced activities (Mates et al.,
2009). The most hyperactive SB transposase version
currently available, SB100X, displays a 100-fold
hyperactivity when compared to the originally resur-
rected transposase (Mates et al., 2009). The hyper-
activity of SB100X cannot be explained by altered
transposase stability, nor by increased binding to the
transposon TIRs; instead, the particular combination of
mutations in SB100X appears to affect the folding
properties of the transposase (Mates et al., 2009). The
SB100X transposase enables highly efficient germline
transgenesis in relevant mammalian models, including
mice, rats, rabbits and pigs (Ivics et al., 2014a, 2014b,
2014c). Moreover, the use of the SB100X system
yielded robust gene transfer efficiencies into human
HSCs (Mates et al., 2009; Xue et al., 2009), mesenchy-
mal stem cells, muscle stem/progenitor cells (myo-
blasts), iPSCs (Belay et al., 2010) and T cells (Jin et al.,
2011). These cells are relevant targets for stem cell
biology and for regenerative medicine and gene- and
cell-based therapies of complex genetic diseases.
Thus, the SB100X hyperactive transposase holds great
promise for of ex vivo and in vivo gene therapies.
Optimized transposons and transposon donor
vectors
The first-generation SB transposon vector (called pT)
was based on a naturally occurring sequence originally
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isolated from the Tanichthys albonubes genome (Ivics
et al., 1997). As with the transposase, although to a
lesser extent, mutagenesis of the SB TIR sequences has
been undertaken with the aim to increase the efficiency
of transposition. For example, flanking transgenes by
two left TIRs of SB (instead of the canonical arrange-
ment of one left TIR (LIR) and one right TIR (RIR) (Figure
2(A))) was shown to enhance transposition by 3-fold,
likely due to the presence of a transpositional enhancer
sequence located in LIR (Izsvak et al., 2002).
Replacement of four base pairs in RIR and flanking both
TIRs by a doublet of TAs (i.e. by TATA sequences as
opposed to the canonical TA sites) resulted in 3-fold
increase in transposition over pT (Cui et al., 2002).
Incorporation of a multi-cloning-site consisting of sev-
eral unique restriction enzymes sites available for clon-
ing genes of interests into the optimized transposon
sequences led to the pT2-generation SB transposon
vector, which has become the most popular SB trans-
poson vector in the scientific community. A combin-
ation of the 2-left-TIR and 2-TA arrangements led to a
vector called pT3 (Yant et al., 2004). Finally, optimization
of SB transposase binding to its internal binding sites
within the transposon TIRs by cyclic amplification and
selection of targets (CASTing) recently yielded pT4 with
modest hyperactivity (Wang et al., 2016b). In addition to
enhancing transposition per se, SB vectors of enhanced
utility have been devised, for example by including cas-
settes for constitutive or inducible expression of any
gene of interest in combination with different antibiotic
selection markers and fluorescent reporters (Kowarz
et al., 2015).
Vectorization of Sleeping Beauty components
Plasmid DNA to encode SB transposase and
transposon
The typical setup for delivery of the SB transposon
system into cells is supplying the two components of
the vector system (i.e. the engineered transposon car-
rying a gene of interest and a transposase source) as
conventional plasmids. Although both components
can be placed on a single plasmid (Mikkelsen et al.,
2003) (Figure 2(D)), this arrangement has not become
popular, mainly because it does not allow careful
titration of transposase expression required for opti-
mal transposition at a certain transposon dose.
Because optimal transposon-to-transposase ratio can
substantially vary dependent on cell type, most inves-
tigators opt for the use of the 2-plasmid vector sys-
tem (Figure 2(B)). Two recent developments that
address both the efficiency and safety of SB gene
delivery are the use of mRNA-encoded SB100X and
minicircle (MC) vectors to encode transposase/trans-
poson. Both are key milestones toward the clinical
use of SB transposition.
mRNA as a transient source of SB transposase
The transposase expression plasmid that is typically
used to provide a transposase source in cultured cell
lines can be replaced by mRNA synthesized in in vitro
transcription reactions (Figure 2(E)). Co-delivery of SB
transposase-encoding mRNA with an SB transposon
plasmid to somatic cells was originally tested in a mam-
malian cell line in vitro and in the mouse liver in vivo,
using an early version of the SB transposase, SB11
(described above) (Wilber et al., 2006, 2007). By apply-
ing mRNA for intracellular delivery in therapeutically
relevant cells ex vivo, some hurdles of gene transfer typ-
ical for DNA-based vectors can be avoided. For example,
nucleofection of primary human cells, including HSCs
and T cells, with mRNA was shown to cause significantly
reduced cellular toxicity as compared to nucleofection
with plasmid DNA (Monjezi et al., 2016; Wiehe et al.,
2007). Second, upon transfection, mRNA translocates
into the cytoplasm where it is readily available for the
host translational machinery and protein production.
Finally, the implementation of an mRNA source for tran-
sient delivery of the SB transposase increases the biosaf-
ety of this approach, as mRNA does not bear the risk of
chromosomal integration. In contrast, it is known that
transfection of plasmid DNA is associated with a small,
but non-negligible chance of spontaneous, illegitimate
vector integration into the host genome (Wang et al.,
2004). Genomic integration of the SB transposase cod-
ing sequence into the genome represents a finite risk in
a gene therapy application, because such event could
lead to genomic instability due to prolonged and
uncontrollable transposase expression resulting in con-
tinuous remobilization of the already integrated SB
transposon.
Minicircle DNA – minimalistic transposase and
transposon expression cassettes
A recent addition to the development of SB vectors
with enhanced utility for clinical applications is the use
of MC vectors as carriers of the SB transposon compo-
nents. The MC technology allows for a significant reduc-
tion of SB vector size by removing most of the
backbone sequences from parental plasmids (Sharma
et al., 2013). The presence of bacterial backbone ele-
ments is typically required for vector propagation in
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Escherichia coli, but completely redundant or even
undesired for clinical applications. The first evident
advantage of using MC vectors over plasmids is related
to increased cell survival rates following nucleofection
of human T cells (Monjezi et al., 2016) (described
in detail below in “Cancer immunotherapy with tumor--
reactive CAR T-cells”). Unmethylated CpG motifs, which
are highly enriched in the bacterial backbone of
exogenously delivered plasmids, were shown to trigger
strong inflammatory responses through toll-like recep-
tor-9 (Chuang et al., 2002; Hemmi et al., 2000) and/or
interferon induction (Huerfano et al., 2013). Activation
of these cellular sensors might be a conceivable explan-
ation for the observed cytotoxicity and thus for the loss
of a large fraction of cells transfected with plasmid DNA
from the rest of the proliferating cell culture. Indeed,
removal of CpG motifs from plasmid DNA vectors was
demonstrated to reduce inflammatory responses upon
pulmonary gene delivery (Hyde et al., 2008), and vector
CpG methylation was able to lower immune responsive-
ness towards “non-self” DNA and led to delayed clear-
ance of transfected cells in vivo (Reyes-Sandoval & Ertl,
2004). Along with decreased levels of cytotoxicity,
nucleofection of T cells with SB transposon components
supplied as MCs resulted in enhanced transient gene
delivery and more efficient stable genome modification
as compared to conventional plasmid vectors (Monjezi
et al., 2016) (described in detail below in “Cancer
immunotherapy with tumor-reactive CAR T-cells”).
The MC components are likely more efficient in
transfection than plasmids because, due to their smaller
size, they cross cellular membranes more efficiently
than plasmids (Chabot et al., 2013; Darquet et al., 1997).
Second, MC vectors may support enhanced transcrip-
tion of transgene cassettes. Indeed, enhanced and sus-
tained transgene expression has been seen in episomal
gene therapy applications with MC vectors with con-
comitant gene silencing commencing rapidly after
hydrodynamic injection of parental plasmid vectors
in vivo (Chen et al., 2003; Osborn et al., 2011). Covalent
linkage of bacterial DNA sequences to a eukaryotic
expression cassette has been suggested to facilitate the
spreading of repressive chromatin formed primarily on
the bacterial backbone, leading in turn to rapid loss of
transgene expression from plasmid DNA vectors (Chen
et al., 2004, 2008). Finally, the elevated levels of trans-
position observed with MC vectors are likely supported,
at least in part, by the relatively short, 200 bp distance
between the SB transposon ends in the MC-based trans-
poson vector, owing to the depletion of the bacterial
plasmid backbone. Indeed, SB transposition was shown
to be far more efficient when the length of DNA
sequence outside the transposon unit was shortened,
likely by aiding transposon/transposase complex forma-
tion, as discussed above (Izsvak et al., 2000). In addition
to efficacy, the MC technology also offers biosafety
advantages over conventional plasmid DNA vectors.
Namely, the absence of bacterial plasmid backbone ele-
ments in therapeutic vectors is highly relevant in clinical
applications, because antibiotic resistance genes
included in a therapeutic cell product may raise safety
concerns.
Establishing a biosafety profile
Genome-wide distribution of Sleeping Beauty
insertions
With any vector that integrates into chromosomes in a
semi-random manner comes the potential risk of inser-
tional mutagenesis leading to transcriptional activation
or inactivation of cellular genes (Baum et al., 2004).
Such genotoxic effects can have devastating conse-
quences for the cell and the whole organism, including
the development of cancer, as discussed above in “Viral
gene transfer vectors”.
SB displays considerable specificity in target site
selection at the primary DNA sequence level in that TA
dinucleotides are near-obligate target sites (Vigdal et al.,
2002). A palindromic AT-repeat consensus sequence
with bendability and hydrogen bonding potential was
found to constitute preferred target sites (Vigdal et al.,
2002). It was later shown that a characteristic deform-
ation of the DNA sequence may be a recognition signal
for target selection (Liu et al., 2005). Although character-
ization of the target site selection properties of different
vector systems still falls short of predicting the actual
risk of insertional oncogenesis in a clinical trial, it is
highly useful for ranking the different vector types and
designs according to their genotoxic potential (Naldini,
2011). We have previously undertaken a comparative
study addressing target site selection properties of
the SB and PB transposons as well as MLV-derived
gammaretroviral and HIV-derived lentiviral systems in
primary human CD4þ T cells. Our bioinformatic analyzes
included mapping against the T cell genome with
respect to proximity to genes, transcriptional start sites
(TSSs), CpG islands, DNaseI hypersensitive sites, chroma-
tin marks and transcriptional status of genes. The SB
transposon displayed the least deviation from random
with respect to genome-wide distribution: no apparent
bias was seen for either heterochromatin marks or
euchromatin marks and only a weak correlation with
transcriptional status of targeted genes was detected
(Gogol-Doring et al., 2016). Our compiled datasets also
allowed us to rank these vector systems with respect to
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their projected relative “safety” based on the frequen-
cies of integration into GSHs that were previously pro-
posed to satisfy five criteria: (i) distance of at least 50 kb
from the 5’-end of any gene, (ii) distance of at least
300 kb from any cancer-related gene, (iii) distance of at
least 300 kb from any microRNA (miRNA), (iv) location
outside a transcription unit and (v) location outside
ultraconserved regions of the human genome
(Papapetrou et al., 2011; Sadelain et al., 2012). Our ana-
lyzes collectively established a favorable integration
profile of the SB transposon, suggesting that SB might
be safer for therapeutic gene delivery than the integrat-
ing viral vectors that are currently used in clinical trials.
Importantly, no SB-associated adverse effects have been
observed in preclinical animal studies (Fernando &
Fletcher, 2006; Hackett et al., 2010; Ivics & Izsvak, 2006;
Izsvak et al., 2010).
Vector-associated transcriptional activity
Integration of a vector into a gene or its regulatory ele-
ments can knock out the gene, overexpress the gene or
alter its spatio/temporal expression pattern. The major
underlying mechanism, by which insertional mutagen-
esis manifests in gene therapy appears to be transcrip-
tional trans-activation of oncogenes (Baum et al., 2004;
Deichmann et al., 2007) by the retroviral long terminal
repeats (LTRs) that carry strong enhancer/promoter ele-
ments. Due to their intrinsic preference for integrating
into TSSs (see above), MLV-derived gammaretroviral
vectors are especially prone to transcriptionally upregu-
late endogenous genes. Indeed, it has been demon-
strated that MLV-based gammaretroviral insertions,
although they target GSHs>2-fold more frequently
than HIV-based lentiviral vectors (Gogol-Doring et al.,
2016), were approximately 3-fold more likely to trigger
transformation of primary HSCs in a cell-based immor-
talization assay (Modlich et al., 2009). This suggests that
an MLV insertion next to a TSSs tends to be more geno-
toxic than an HIV insertion in a gene body, in line with
the expectation that gain-of-function due to oncogene
upregulation has a more profound effect on cellular
homeostasis than loss-of-function due to knockout
mutations (unless the affected gene is haplo-insuffi-
cient). To ameliorate vector-induced insertional onco-
genesis, second-generation, self-inactivating (SIN)
vectors have been developed for both gammaretroviral
and lentiviral vectors. These vectors lack transcriptional
enhancer/promopter elements in their LTRs
(Schambach et al., 2006, 2007), and therefore they are
expected to have an enhanced safety profile in clinical
applications. Indeed, SIN vectors result in reduced
clonal immortalization in cell-based genotoxicity assays
(Modlich et al., 2009).
Unlike the LTRs of retroviruses, the TIRs of SB vectors
have negligible enhancer/promoter activity (Moldt et al.,
2007; Walisko et al., 2008). The left TIR of SB is separated
from the transposase coding sequence by a 5’-UTR of
160 bp stretch of DNA with no apparent function in the
transposition reaction (Zayed et al., 2004). As measured
by transient reporter assays, transcription driven by the
5’-UTR of SB is 18-fold higher than transcription of a
promoter-less sequence, and 5-fold higher than tran-
scription driven by a TATA-box minimal promoter
(Walisko et al., 2008). Importantly, the 5’-UTR is not pre-
sent in SB transposon vectors (because it is dispensable
for transposition). Thus, contemporary SB vectors are
transcriptionally neutral, and therefore it is expected
that their mutagenic potential will largely depend on
their cargo (including the transcriptional regulatory ele-
ments that drive transgene expression).
Beyond the genomic integration pattern and the
transcriptional activities associated with a given vector,
a third determinant of risk stemming from vector inte-
gration is the type of cell, in which therapeutic gene
transfer is executed. In contrast to HSC-based gene
therapy, leukemia was never observed in preclinical ani-
mal models or clinical trials involving gene transfer into
peripheral blood-derived T lymphocytes (Newrzela
et al., 2008; Recchia et al., 2006). Thus, mature T cells
seem to be less susceptible to transformation by geno-
toxic events than are HSCs. It is likely that other types
of terminally differentiated cells, including retinal pig-
ment epithelium (RPE) cells isolated from the eye are
also more refractory to oncogenic transformation than
stem cells (Balaggan et al., 2012), thereby presenting
attractive targets for Phase I clinical trials.
Clinical application of Sleeping Beauty gene
delivery
Overview
The past few years have seen a steadily growing interest
in applying SB transposition in gene therapy to provide
innovative and potentially curative treatments for gen-
etic disorders [reviewed in (Boehme et al., 2015; Essner
et al., 2005; Hackett et al., 2005, 2010, 2011; Ivics &
Izsvak, 2006, 2011; Izsvak & Ivics, 2004; Izsvak et al.,
2010)]. Prime examples for the use of SB in gene therapy
include the treatment of hematologic disorders, lyso-
somal storage diseases, pulmonary disorders, dermato-
logic diseases, a variety of metabolic disorders,
neurologic disorders, muscle disorders and cancer
(Table 1).
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In addition, important steps have been made toward
SB-mediated gene transfer in the eye to treat neovascu-
lar age-related macular degeneration (AMD), which will
be discussed in detail in “Sleeping Beauty non-viral gene
delivery for gene therapy of neovascular age-related
macular degeneration”, as an example for successful
clinical translation. Further, a medical revolution is cur-
rently taking place in the field of hematology and oncol-
ogy with the successful clinical use of genetically
modified tumor-reactive T cells that are equipped with
synthetic chimeric antigen receptors (CARs) or trans-
genic T-cell receptors (TCRs). Clinical-proof-of-concept
has been obtained with both CAR-modified T cells in
advanced hematologic malignancies and TCR-transgenic
T cells in hematologic and solid tumors (Davila et al.,
2014; Kochenderfer et al., 2015; Maude et al., 2014;
Morgan et al., 2006; Rapoport et al., 2015, Turtle et al.,
2016a, 2016b; Turtle & Maloney, 2016). Intriguingly, the
concept of endowing T cells with a novel specificity
through CAR- and TCR-gene transfer is already being
adopted to also treat infections and autoimmune dis-
eases and will establish novel treatment paradigms in
medicine. As a prime example, the use of SB-mediated
gene transfer to engineer CAR-modified T cells for anti-
Table 1. Preclinical studies with Sleeping Beauty gene transfer in disease models.
Indication Method of delivery Site of delivery References
Hematologic disorders
Hemophilia A and B Tail vein hydrodynamic injection of
naked DNA
In vivo, mouse liver (Yant et al., 2000; Ohlfest et al.,
2005b)
Intravenous injection of DNA/polye-
thyleneimine (PEI) complexes
In vivo, mouse lungs (Liu et al., 2006b)
Intravenous injection of nanocapsules In vivo, mouse liver (Kren et al., 2009)
Intravenous injection of adenovirus/SB
hybrid vector
In vivo, dog liver (Hausl et al., 2010)
Sickle cell disease Transfection In vitro, human cell lines (Zhu et al., 2007)
Tail vain hydrodynamic injection of
naked DNA
In vivo, mouse liver (Belcher et al., 2010)
Lysosomal storage diseases
Mucopolysaccharidosis Tail vein hydrodynamic injection of
naked DNA
In vivo, mouse liver (Aronovich et al., 2007, 2009)
Pulmonary disorders
Fibrosis Intravenous injection of DNA/polye-
thyleneimine (PEI) complexes
In vivo, mouse lungs (Xiao et al., 2012)
Pulmonary hypertension Intravenous injection of DNA/polye-
thyleneimine (PEI) complexes
In vivo, rat lungs (Liu et al., 2006a)
Dermatologic disorders
Junctional epidermolysis bullosa Transfection Ex vivo, patient epidermis (Ortiz-Urda et al., 2003)
Dystrophic epidermolysis
bullosa
Transfection Ex vivo, human keratinocytes, fol-
lowed by xenograft in mice
(Latella et al., 2016)
Metabolic disorders
Tyrosinemia type I Tail vain hydrodynamic injection of
naked DNA
In vivo, mouse liver (Montini et al., 2002; Wilber
et al., 2007; Pan et al., 2012)
Diabetes type I Tail vain hydrodynamic injection of
naked DNA
In vivo, mouse liver (He et al., 2004)
Hypercholesterolemia Tail vain hydrodynamic injection of
naked DNA
In vivo, mouse liver (Turunen et al., 2016)
Crigler-Najjar syndrome type I
(hyperbilirubinemia)
Intravenous injection of
proteoliposomes
In vivo, mouse liver (Wang et al., 2009)
Neurologic disorders
Huntington disease Transfection In vitro, human cell lines (Chen et al., 2005)
Alzheimer’s Transfection followed by encapsulated
cell biodelivery
In vitro, human cell line, followed
by graft in patient brain
(Eyjolfsdottir et al., 2016)
Muscular dystrophy
Transfection In vitro, mouse cell line, followed
by transplantation into mice
(Muses et al., 2011)
Transfection Ex vivo, mouse myoblasts, followed
by transplantation into mice
(Escobar et al., 2016)
Cancer
Electroporation, TCR gene transfer Ex vivo, human PBMCs or T cells (Peng et al., 2009; Deniger
et al., 2016)
Electroporatiion, CAR gene transfer Ex vivo, human PBMCs or T cells (Huang et al., 2008; Singh et al.,
2008; Jin et al., 2011,
Magnani et al., 2016)
Transfection In vitro, hepatocellular carcinoma
cell lines
(Song et al., 2009)
Intratumoral injection In vivo, human glioblastoma xeno-
grafts in mice
(Ohlfest et al., 2005a)
Tail vain hydrodynamic injection of
naked DNA
In vivo, mouse liver (Belur et al., 2011)
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cancer therapy will be discussed in detail in “Cancer
immunotherapy with tumor-reactive CAR T-cells”.
Sleeping Beauty non-viral gene delivery for gene
therapy of neovascular age-related macular
degeneration
TargetAMD is an international consortium of univer-
sities, research institutes and commercial organizations
funded by the European Commission to execute a
Phase Ia/IIb clinical trial for the treatment of neovascu-
lar AMD by transplantation of genetically modified,
autologous retinal pigment epithelial (RPE) or iris pig-
ment epithelial (IPE) cells that overexpress pigment epi-
thelial-derived factor (PEDF) to the subretinal space of
the eye. Specifically, RPE or IPE cells isolated from the
peripheral retina or obtained from an iris biopsy of a
patient will be transfected with an SB transposon vector
carrying a PEDF expression cassette and transplanted
back into the same patient during one surgical session
lasting about 60min.
AMD is a major cause of acquired irreversible
blindness in adults
AMD refers to the degeneration of RPE cells in the mac-
ula area (Figure 3), which is essential for central vision.
With over 13 million people affected, AMD is the fourth
most common cause of blindness after cataract,
retinopathy of prematurity, and glaucoma in the world
and the leading cause of irreversible blindness in peo-
ple aged>50 years in developed countries (Velez-
Montoya et al., 2014). There are two forms of AMD:
avascular AMD (avAMD) or geographic atrophy (GA)
and neovascular AMD (nvAMD), which is characterized
by the subretinal invasion of choroidal vessels. Whereas
avAMD is a slow progressing disorder, in which photo-
receptor degeneration follows RPE cell degeneration,
nvAMD progresses rapidly to blindness following RPE
cell degeneration. No treatments are available for
avAMD.
Limited clinical benefit of AMD from
antibody-mediated VEGF blockade
Since overexpression of vascular endothelial growth fac-
tor (VEGF) has been shown to be responsible for the
development of subretinal neovascularization underly-
ing the development of nvAMD (Ohno-Matsui et al.,
2001; Velez-Montoya et al., 2014), its current treatment,
which is effective in 30–40% of patients, is based on
monthly, life-long, intravitreal injections of inhibitors of
VEGF. The three most commonly used anti-VEGFs are
bevacizumab (AvastinVR , Genentech, San Francisco, CA),
its Fab fragment ranibizumab (LucentisVR , Genentech)
and aflibercept (EyleaVR , Regeneron, Tarrytown, NY),
which is a recombinant fusion protein consisting of the
extracellular binding domains of human VEGF receptors
1 and 2 fused to the Fc portion of the human IgG1
immunoglobulin.
The two major limitations of anti-VEGFs are the lack
of improvement of vision in 60–70% of patients and
adverse effects (Nesmith et al., 2014) including more
rapid progression of GA (Enslow et al., 2016), increased
intraocular pressure, retinal detachment, endophthalmi-
tis, photoreceptor cell death and thinning of the inner
neuronal layer of the retina (Saint-Geniez et al., 2008;
Scott & Bressler, 2013). In addition to the adverse
effects, the issues associated with logistics of blind or
low-vision patients traveling to a clinic on a monthly
basis result in a significant number of patients discon-
tinuing treatment, which has been reported to be from
57% over five years (Boulanger-Scemama et al., 2015) to
as high as 71% within 24months (Lad et al., 2014).
Therefore, it is evident that new approaches are
required for the efficient treatment of nvAMD.
One-shot AMD treatment: Sleeping Beauty-based
PEDF gene therapy
The evidence that nvAMD is caused by RPE cell degen-
eration has engendered the hypothesis that the condi-
tion could be treated by replacing the degenerated RPE
Figure 3. Neovascular age-related macular degeneration
(nvAMD). In nvAMD choroidal neovascularization (CNV) due to
an imbalance of pro- and anti-angiogenic factors like VEGF
and PEDF leads to severe hemorrhages damaging the retinal
pigment epithelium (RPE) and the neural retina. The fundu-
scopic image illustrates such a bleeding (arrow) in advanced
nvAMD (see colour version of this figure at www.tandfonline.
com/ibmg).
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cells with healthy RPE cells, which synthesize and
secrete the anti-angiogenic and neuroprotective factor
pigment epithelium-derived factor (PEDF) in vivo.
Administration of recombinant PEDF is not feasible
because of its short half-life, and transplantation of RPE
or IPE cells, as a substitute for degenerated RPE cells,
has not resulted in significant improvement in visual
acuity in nvAMD patients (Aisenbrey et al., 2006; Binder
et al., 2004; Falkner-Radler et al., 2011; Lappas et al.,
2004), indicating that the replacement cells did not
express anti-angiogenic factors at sufficient levels to
overcome the pathologic overexpression of VEGF.
Therefore, a desirable alternative to overcome the
difficulties associated with frequent, life-long intravitreal
injections would be a treatment modality that introdu-
ces an inhibitor of neovascularization to the retina that
would last for the life of the patient. To meet such
treatment modality, Campochiaro and colleagues
(Campochiaro et al., 2006) delivered a PEDF transgene
cassette to the retina of nvAMD patients using an
adenoviral vector, and reported significant improve-
ment in 25% of patients after 12weeks and no harmful
side effects. However, no follow-up to the trial has been
reported. Currently, four clinical trials are ongoing
(www.clinicaltrials.gov): i) trial NCT01494805 (Avalanche
Biotechnologies, Menlo Park, CA), phase I/II, that
employs a recombinant adeno-associated viral (rAAV)
vector encoding sFlt-1, a splice variant of VEGF receptor
1, by subretinal delivery to nvAMD patients; ii) trial
NCT01024998 (Genzyme, Cambridge, MA), phase I, that
delivers an rAAV vector encoding sFLT01, a fusion pro-
tein that consists of the VEGF binding domain of sFlt-1
fused to the Fc portion of human IgG1, by a single intra-
vitreal injection in nvAMD patients; iii) trial
NCT01301443 (Oxford Biomedica, Oxford, UK), phase I,
that delivers a lentiviral vector encoding endostatin and
angiostatin, both inhibitors of VEGF (RetinoStatVR ), subre-
tinally to nvAMD patients; and iv) trial NCT01678872
(Oxford Biomedica), phase I, that is a 15-year trial to
determine safety and efficacy of subretinal RetinoStatVR
encoded in a lentiviral vector in nvAMD patients
enrolled in the NCT01301443 trial.
As discussed earlier, viral vectors, although efficient
at gene delivery, have limitations in human use; since
adenoviral and rAAV vectors remain episomal and read-
ministration may elicit immune responses (Basner-
Tschakarjan & Mingozzi, 2014; Dijkhuizen et al., 1998;
Hermens & Verhaagen, 1997; Tse et al., 2015), while len-
tiviral and gammaretroviral vectors have a preference
for transgene integration into transcriptionally active
genomic regions that could result in insertional muta-
genesis and aberrant expression of endogenous genes
(Cesana et al., 2012; Hacein-Bey-Abina et al., 2008;
Hargrove et al., 2008) with potentially detrimental con-
sequences for the patient.
In nvAMD, choroidal blood vessel growth into the
subretinal space not only disorganizes the normal archi-
tecture of the retina, but leads to RPE cell degeneration
and loss of vision. The use of vectors to deliver inhibi-
tors of neovascularization to the subretinal space of
nvAMD patients will benefit only those patients that
have normally functioning RPE cells. However, due to
advanced RPE cell degeneration, 60–70% of nvAMD
patients do not benefit from anti-VEGF treatment, and
thus replacement of the degenerated RPE cells appears
essential to regain vision. Since transplantation of RPE
or IPE cells does not have a significant effect on chor-
oidal neovascularization (CNV), the hallmark of nvAMD,
and does not improve vision in nvAMD patients, we
have hypothesized that transplantation of genetically
modified RPE or IPE expressing PEDF at supra-physio-
logical levels would not only replace the degenerated
cells, but at the same time could inhibit CNV, prevent
the continued degeneration of RPE cells, and restore
vision in nvAMD patients (Figure 4).
Local delivery of PEDF through SB-engineered
autologous RPE/IPE cells
Because the inhibition of VEGF must be constant and
the proper balance between angiogenic and anti-angio-
genic activities must be maintained for the life of the
patients for an effective gene therapy of nvAMD, stable
transgene integration and continuous PEDF expression
are critical for re-acquiring vision. To avoid the risks
accompanied by gene delivery mediated by viral vec-
tors, the TargetAMD consortium has been pursuing the
use of the hyperactive SB100X system for efficient deliv-
ery of a human PEDF transgene cassette to cultured and
freshly isolated RPE and IPE cells (Figure 4(A,B)).
Importantly, cells transfected with a PEDF-transposon
and the SB100X transposase have been found to
express recombinant PEDF long-term for the duration
of 16months that the cells have been in culture (Figure
4(C)) (Johnen et al., 2012). Genome-wide insertion site
analysis in human RPE cells established a close-to-ran-
dom insertion profile of SB and a frequency of inserting
into GSHs similar to that found in human T cells (Gogol-
Doring et al., 2016; Monjezi et al., 2016; Thumann et al.,
2017). Importantly, no insertions were observed in
genes critical to RPE cell function, including the angio-
genic factor VEGF-A, the visual cycle protein CRALBP,
the lysosomal enzyme cathepsin D, the tight-junction
protein ZO-1 and the cytokeratin KRT8. SB100X-medi-
ated stable gene transfer of PEDF in the human RPE cell
line ARPE-19 cells, followed by subconjunctival
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transplantation in a rabbit model significantly sup-
pressed and prevented neovascularization (Kuerten
et al., 2015). To establish whether RPE cells expressing
elevated levels of PEDF inhibit CNV, 10.000 rat RPE cells
transfected with the PEDF gene using SB100X and
secreting approximately 2 ng PEDF/day were trans-
planted to the subretinal space of rats in which CNV
was induced by laser rupture of Bruch’s membrane
(Grossniklaus, et al., 2010). A marked reduction of neo-
vascularization was observed at 7 and 14 d post-
transplantation, with the area of neovascularization
reduced by 50% (Figure 4(E)) (Johnen et al., 2015).
It has been demonstrated that, by using SB trans-
poson plasmids in conjunction with the SB100X trans-
posase, the PEDF gene can be efficiently delivered to
IPE cells; however, although safer than viral vectors,
plasmids carry antibiotic resistance genes, e.g. the
pT2 SB transposon vector (Cui et al., 2002) carries an
ampicillin-resistance gene, which is necessary for plas-
mid maintenance in E. coli, and thus for efficient
Figure 4. Gene therapy to treat neuroretinal degeneration. A) The anatomy of the human eye is shown. Image source: National
Eye Institute, NIH. A small biopsy is taken from the patient’s iris for the isolation of 10.000 IPE cells that are taken in culture in
an appropriate buffer. B) The IPE cells are electroporated ex vivo with components of the SB transposon system: a transposon car-
rying the therapeutic PEDF transgene or a Venus reporter and the SB100X transposase. C) Stable transfection and gene expression
in primary human IPE cells. For the analysis of Venus reporter gene expression, human IPE cells were isolated post mortem, and
taken in culture for four weeks before transfection with the transposon system components. For the analysis of PEDF expression,
human IPE cells were isolated from donor tissue, and taken in culture for 8–12 weeks before transfection with the transposon sys-
tem components. Expression of Venus (micrographs) and secretion of human PEDF (Western blot) at early (10 and 20 days) and
late (150 days) indicate stable gene transfer and transgene expression. D) Genetically engineered IPE cells expressing and secret-
ing human PEDF are grafted onto the patient’s retina. E) PEDF-transfected cells significantly reduced CNV in rats in vivo and cor-
neal neovascularization in rabbits (Johnen et al., 2015; Kuerten et al., 2015). Shown here are retinal flat mounts of rats treated
with laser to provoke CNV. Lesions are stained with FITC-conjugated isolectin B4 at day 14 post-transplantation. In non-injected
(No Injection), sham-treated (Sham) animals and after transplantation of Venus-transfected cells (Venus) lesions are unaltered,
whereas after transplantation with PEDF-transfected cells (rPEDF) lesion size was significantly reduced (see colour version of this
figure at www.tandfonline.com/ibmg).
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manufacturing of the plasmid vector. The presence of
antibiotic resistance markers in gene therapy vectors is
a matter of concern, since there is a risk that the anti-
biotic resistance genes could elicit resistance to patho-
genic bacteria by horizontal gene transfer and residues
of antibiotics could contaminate the final product, plac-
ing patients with severe hypersensitivity to antibiotics
at risk (Solensky, 2003). In fact, regulatory agencies rec-
ommend that antibiotic resistance genes be eliminated
from gene therapy treatments whenever possible. Thus,
the TargetAMD consortium resorted to apply a variant
of MC technology in free of antibiotic markers (pFAR)
miniplasmids (Marie et al., 2010). Like MCs, pFAR-based
vactors lack antibiotic-resistance genes, thereby signifi-
cantly enhancing the safety profile of nonviral gene
delivery in clinical settings.
TargetAMD: Phase I clinical trial of SB-based PEDF
gene therapy launched in 2017
The ultimate goal of TargetAMD is to perform a Phase
Ia/IIb clinical trial in which IPE cells will be isolated from
an iris biopsy of a nvAMD patient, transfected with the
PEDF gene and transplanted to the subretinal space of
the same patient during a single surgical session lasting
approximately one hour (Figure 4). Since the isolation
of IPE or RPE cells from a patient’s biopsy yields a lim-
ited number of cells, and since safety is a major concern
of any therapy, and of gene therapy in particular, we
have developed a protocol for the efficient delivery of
the PEDF gene in as few as 5.000–10.000 freshly isolated
IPE and RPE cells from human donor eyes by vectorizing
the PEDF-encoding SB transposon and the SB100X
transposase in pFAR miniplasmids (Marie et al., 2010;
Thumann et al., 2017). Using this protocol, a standard
operating procedure has been established that i) con-
sistently shows highly efficient transfer of the PEDF
gene in RPE and IPE cells obtained from donor eyes, ii)
enables expression of recombinant PEDF at high levels
of recombinant protein in cultured PEDF-transfected
cells, and iii) allows for sustained transgene expression
(for over one year that the cells have been in culture) in
genetically engineered cells. The robustness of this pro-
cedure is coupled with salient safety features including
a close-to-random transgene integration profile of the
SB transposon in human IPE and RPE cells and the lack
of antibiotic resistance genes in vector components.
Based on the results described here and approval by
the Swissmedic regulatory agency, TargetAMD will
begin patient recruitment for the phase Ia/IIb clinical
trial in the spring of 2017 and expects to complete the
first European in-man clinical trial using SB transposon
and pFAR technologies.
Cancer immunotherapy with tumor-reactive CAR
T-cells
Adoptive immunotherapy with tumor-reactive T cells
that are engineered by gene transfer to express a
synthetic CAR is emerging as an effective and poten-
tially curative treatment for advanced malignancies.
CARs are designer molecules comprised of an extra-
cellular antigen binding domain, most commonly the
variable light and heavy chains of a monoclonal anti-
body, a spacer and transmembrane region that
anchors the receptor on the T-cell surface and pro-
vides reach and flexibility for binding the target epi-
tope, and an intracellular signaling module, most
commonly CD3 zeta and one or more costimulatory
domains, that mediate T-cell activation after antigen
binding (Sadelain et al., 2013; Srivastava & Riddell,
2015) (Figure 5). The genetic information required for
encoding a CAR is 1–2 kb depending on binding
domain configuration, spacer length and the number
of costimulatory moieties.
A medical revolution: CAR T-cell immunotherapy for
B-cell malignancies
The most advanced clinical development is the use of
CARs specific for the B-lineage marker CD19 that is
expressed on B-cell acute and chronic lymphocytic leuke-
mia and B-cell lymphoma. Several groups have reported
up to 90% complete remissions in patients with chemo-
therapy- and radiotherapy-refractory B-cell acute
lymphoblastic leukemia (ALL) and>60% complete remis-
sions in patients with non-Hodgkin lymphoma (NHL)
after administration of autologous (i.e. patient-derived)
CD19-CAR T cells (Davila et al., 2014; Kochenderfer et al.,
2015; Lee et al., 2015; Maude et al., 2014; Turtle et al.,
2016a, 2016b; Turtle & Maloney, 2016) (Table 2). These
results are considered by many to be a medical break-
through, given the advanced disease stage and failure of
conventional treatments in many patients that were
included in these clinical trials. Side effects of CD19-CAR
T-cell therapy are a consequence of the strong anti-
tumor immune response and include tumor lysis syn-
drome due to the rapid destruction of a large number of
tumor cells, cytokine release syndrome due to the rapid
release of cytokines by CAR T cells and other immune
cells, and the depletion of normal B-cells due to their
physiologic expression of CD19.
Viral gene transfer vectors dominate pre-clinical and
clinical studies with CAR T cells
The overwhelming majority of pre-clinical work and
clinical trials that reported efficacy of CD19-CAR T-
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cell therapy has employed gammaretroviral and lenti-
viral vectors to stably integrate the genetic informa-
tion of the CD19-CAR in patient’s T cells (Table 2).
As a consequence, the CAR is not only expressed in
T cells that are modified and infused to the patient,
but also in subsequent generations of daughter T
cells after cell division and propagation. The use of
stable gene transfer systems is consistent with the
concept and conducive to the ambition of CAR T-cell
immunotherapy that administration of a small num-
ber of patient-derived CAR T cells is sufficient to
achieve engraftment and proliferation in vivo until all
tumor cells have been cleared and persistence as
memory CAR T cells that protect the patient from
tumor relapse long-term.
The potential to achieve transient CAR expression in
T cells through transfection of mRNA has been demon-
strated and results in CAR surface expression for up to
several days which can be sufficient to induce an anti--
tumor effect, especially when high doses of CAR T cells
are administered (Beatty & Moon, 2014; Caruso et al.,
2016). However, because of the rapid decline in CAR
expression, multiple subsequent administrations are
required to sustain the therapeutic effect. A problem
with administering sequential doses of CAR T cells is
the induction of immune responses to immunogenic
Table 2. Clinical trials with CD19-CAR T cells.
CAR targeting domain/co-stim/vector T-cell dose/kg Entity CR rate References
FMC63/4-1BB LV 0.8 10e6–21 10e6 ALL 90% (27/30) (Maude et al., 2014)
SJ25C1/CD28 RV 3 10e6 ALL 88% (14/16) (Davila et al., 2014)
FMC63/4-1BB LV 2 10e5–2 10e6 ALL 86% (25/29) (Turtle et al., 2016a)
FMC63/4-1BB LV 2 10e5–2 10e6 NHL 50%a (10/20) (Turtle et al., 2016b)
CAR: chimeric antigen receptor; LV: lentivirus; RV: retrovirus; ALL: acute lymphoblastic leukemia; NHL: non-Hodgkin lymphoma; CR: complete remission
aIn patients who received a lymphodepleting preparative regimen with fludarabine/cyclophosphamide, the CR rate at the maximum tolerated CAR T-cell
dose level was 64%.
Figure 5. Chimeric antigen receptors (CARs) are synthetic designer molecules. A) The CAR is a synthetic molecule that can be
designed using specialized software, a gene encoding the desired aminoacid sequence synthesized and introduced into cells by
an electroporation unit. B) CARs consist of an extracellular antigen binding domain (e.g. the variable light and heavy chains of a
monoclonal antibody shown in yellow), a spacer and transmembrane region and an intracellular signaling domain (e.g. CD3 zeta
and one or more costimulatory domains shown in blue). C) Expression of the CAR enables T cells (yellow) to recognize surface
molecules on tumor cells (grey) and exert their anti-tumor effector function such as the release of cytolytic granules (triangles)
and cytokines (circles). D) To manufacture a CAR T-cell product, white blood cells are obtained from the patient or a matched
donor, CD8þ killer and CD4þ helper T cells isolated, the genetic information for the CAR introduced, CAR-modified T cells
expanded and administered to the patient (see colour version of this figure at www.tandfonline.com/ibmg).
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epitopes that may be harbored in the targeting domain
(that are often of murine or other “foreign” origin), and
fusion sites in the synthetic CAR molecule. Such
immune responses may lead to rapid and sometimes
fulminant CAR T-cell rejection with loss of the thera-
peutic effect (Maus et al., 2013).
Sleeping Beauty and CAR T cells: clinical
proof-of-concept obtained
The potential to use SB transposition to integrate the
genetic information of the CAR into T cells has first
been explored by the group of Cooper et al. (Singh
et al., 2008). It was demonstrated that SB transposase
can be provided either as plasmid DNA or mRNA in
combination with a plasmid-encoded CAR transposon
and introduced into T cells by electroporation to yield
functional CD19-CAR T cells. Consistent with observa-
tions in other mammalian cell types, the use of SB11
and hyperactive SB100X accomplished higher rates of
gene transfer than first-generation SB transposase (Jin
et al., 2011; Singh et al., 2013). The same group has also
provided the successful clinical debut of SB-engineered
CD19-CAR T cells, and recently reported results of
two pilot clinical trials in 26 patients with ALL and
NHL who had undergone autologous (n¼ 7,
ClinicalTrials.gov Identifier 00968760) or allogeneic
(n¼ 19, ClinicalTrials.gov Identifier NCT01497184) HSC
transplantation (HSCT) prior to CAR T-cell therapy
(Kebriaei et al., 2016). From these clinical studies, it was
concluded that the administration of SB-engineered
CD19-CAR T cells is safe, and may provide additional
tumor control in patients after HSCT. The SB transpos-
ition strategy pursued in this trial was relatively “basic”,
and comprised the nucleofection of plasmid-encoded
SB11 transposase and a plasmid-encoded, pT-based
CAR transposon, followed by ex vivo propagation of
CAR-modified T cells for 28 days (four stimulation
cycles with artificial antigen presenting cells). These
studies are the first CAR T cell clinical trials that rely on
non-viral SB-based gene transfer, and provide proof-of-
concept for the utility of SB transposition in CAR T-cell
engineering. However, because CD19-CAR T cells were
administered as an adjuvant therapy after HSCT, the
presented data are somewhat less spectacular than the
dramatic and durable anti-tumor responses with some-
times year-long persistence of CD19-CAR T cells that
have been reported in other clinical trials that used viral
gene transfer vectors and administered CD19-CAR T
cells outside the HSCT setting (Maude et al., 2014; Turtle
et al., 2016a, 2016b). We would like to point out, how-
ever, that comparisons between clinical trials of CAR
therapy conducted by different groups are difficult due
to multiple variations in study design and clinical
parameters of their patient population. Further, there
are significant differences between trials in the specific
design of CD19-CAR constructs, the CAR T-cell manufac-
turing process, CAR T-cell dose and subset composition,
all of which are factors that we and others have shown
significantly affect clinical safety and efficacy (Hudecek
et al., 2015; Sommermeyer et al., 2015).
In our view, the use of SB transposition is a prefer-
able gene transfer strategy for CAR T-cell engineering.
The clinical trials reported by Kebriaei et al. (2016) pro-
vide a first benchmark; however, manufacturing and
clinical performance of SB-engineered CD19-CAR T-cell
products may be enhanced by the use of: i) an SB trans-
posase (SB100X) and transposon (pT2) with enhanced
transposition rate (see above in “Enhancing Sleeping
Beauty’s performance index”); ii) improved vectorization
and transfection techniques that achieve higher gene
transfer rates at lower toxicity, and enable iii) a short
ex vivo manufacturing process with optimal fitness of
CAR T cells at the time of infusion.
Enhanced CAR T-cell engineering with minicircle-
encoded SB100X and CAR transposon
We have recently shown that vectorization of SB100X
and a pT2-based CAR transposon as MC DNA (Figure
6(A)) dramatically improves transposition efficacy
(Monjezi et al., 2016). Our experience with CD19-CAR T
cells is that the gene transfer rate is 5-fold higher with
the use of MCs compared to conventional plasmids
(Figure 6(B)). Importantly, despite higher transposition
rates, the toxicity of transfecting MCs into T cells is
lower compared to standard DNA plasmids (Monjezi
et al., 2016). As a consequence, therapeutic doses of
CD19-CAR T cells from 1 10e6 input T cells can be
obtained within as short as 14 days with our MC-based
SB approach, and the manufacturing process can be fur-
ther trimmed to only a few days if higher input T-cell
numbers are utilized. Similarly effective, and preferable
from a regulatory point of view, is the use of mRNA-
encoded SB100X in combination with a MC-encoded
CAR transposon. CD19-CAR T cells that we engineered
with the mRNA-MC (and the MC-MC) combination con-
fer potent anti-tumor responses in vitro and in vivo
(Figure 6(C)), and are equally functional as CD19-CAR
T cells prepared by lentiviral transduction (Monjezi
et al., 2016).
We have undertaken a careful analysis of genomic
insertion sites and found a close-to-random insertion
profile of CAR transposons after mobilization from MCs,
consistent with previous studies where SB transposition
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had occurred from conventional pT2 transposon donor
plasmids (Gogol-Doring et al., 2016). A substantial frac-
tion and indeed higher number of CAR transposon
insertions compared to lentiviral integrants had
occurred in GSHs of the T-cell genome that are neither
expected to cause genotoxicity, nor to induce malig-
nant transformation of their host cells as has been
described for gammaretroviral vectors after gene ther-
apy in HSCs (Hacein-Bey-Abina et al., 2003; Monjezi
et al., 2016; Sadelain et al., 2012). Importantly, no case
of malignant transformation has thus far been reported
in clinical trials of CD19-CAR T-cell therapy that
employed viral (and non-viral) gene transfer vectors.
However, in some patients that achieved remission of
their disease, the therapeutic effect was apparently
mediated by single CD19-CAR T-cell clones that
expanded in vivo to comprise a significant proportion of
the patient’s peripheral T-cell repertoire. Based on the
available data, the potential for malignant transform-
ation after CAR gene transfer in human T cells is antici-
pated to be very low. However, especially once larger
cohorts of patients are treated, non-viral SB transpos-
ition may be preferable to gammaretroviral and
lentiviral gene transfer vectors due to its ‘safer’ genomic
integration profile.
Clinical trial with CAR T cells engineered by Sleeping
Beauty transposition from minicircle vectors
A clinical trial with CD19-CAR T cells that are engineered
by SB transposition from MC vectors is in preparation at
the Universit€atsklinikum W€urzburg, Germany, to obtain
clinical proof-of-concept for this novel approach. In this
trial, a CD19-CAR construct will be employed that has
been selected from pre-clinical analyzes due to optimal
anti-tumor function, and has been validated in clinical
trials of CD19-CAR therapy that relied on lentiviral gene
transfer (Hudecek et al., 2015; Turtle et al., 2016a).
Further, cell products that contain equal proportions of
CAR-modified CD8þ killer and CD4þ helper T cells will
be formulated, based on our previous work which
showed this is advantageous to the use of cell products
with random subset composition (Sommermeyer et al.,
2015). The key advantages of CAR T-cell products with
defined subset composition are that i) lower total num-
bers of CAR T cells are sufficient for clinical efficacy
Figure 6. Anti-tumor function of CD19-CAR T cells engineered by Sleeping Beauty transposition. A) Schematic of minicircle (MC)
DNA vectors encoding SB100X transposase and CD19-CAR transposon. MCs are prepared from parental conventional plasmids
through site-specific intramolecular recombination. MCs contain exclusively the transgene and its promoter, but no bacterial origin
of replication and antibiotic resistance genes. EF1, elongation factor-1 alpha promoter; CMV, cytomegalovirus promoter; ORI, bac-
terial origin of replication; AntibxR, antibiotic resistance gene; LIR, left inverted repeat; RIR, right inverted repeat; open cir-
cle¼ recombination site. B) CAR expression in CD8þ killer T cells after transfection of MC- vs. plasmid-encoded SB100X
transposase and CD19-CAR transposon. Flow cytometric analysis was performed on day 14 and shows a significantly higher per-
centage of CAR-modified T cells after transfection of MCs compared to plasmids. C) Anti-tumor efficacy of CD19-CAR T cells pre-
pared by SB-transposition in a murine xenograft model of systemic B-cell lymphoma. Immunodeficient NSG mice were inoculated
with firefly-luciferase expressing Raji lymphoma cells and treated with 5 10e6 CD19-CAR T cells (1:1 ratio of CD8þ and CD4þ T
cells, 2.5 10e6 each) that had been generated by transfection with SB100X mRNA and CD19-CAR MC or control unmodified T
cells. Bioluminescence images were obtained before T-cell infusion (pre, upper row) and 7 days after T-cell infusion (post, lower
row) and show complete lymphoma eradication in the SB CD19-CAR T-cell group, whereas control mice present with progressive
disease. A–C) modified from Monjezi et al. (2016) (see colour version of this figure at www.tandfonline.com/ibmg).
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which reduces the risk for side effects and shortens the
manufacturing process; and ii) because of less product-
to-product variability between patients, the time to and
level of CAR T-cell engraftment and proliferation is
more consistent and predictable, and allows establish-
ing dose-response relationships as well as immune
pharmacokinetic and pharmacodynamic parameters for
CAR T cells as medicinal products. We have determined
the copy number of the CD19-CAR transposon in both
CD8þ and CD4þ T cells, and found it to be in an accept-
able range (n¼ 6 and n¼ 5, respectively), similar to that
obtained with gammaretroviral and lentiviral vectors
(Monjezi et al., 2016).
For future clinical trials, there is a pre-clinical devel-
opment pipeline with CARs specific for target antigens
in other hematologic and solid tumors, including a
SLAMF7-specific CAR in multiple myeloma, and a ROR1-
specific CAR in lymphoma, breast and lung cancer
(Berger et al., 2015; Hudecek et al., 2013).
Importantly, the MC-encoded SB transposon can accom-
modate additional genetic cargo without compromising
transposition efficacy. Our CAR transposon includes an
EGFRt marker that was developed in Mike Jensen’s
laboratory and serves multiple functions, e.g. to select
CAR-modified T cells to further refine the infusion prod-
uct, and to detect CAR T cells in blood and tissue sam-
ples (Wang et al., 2011). Further, CD19-CAR_EGFRt
T cells can be depleted through administration of an
anti-EGFR antibody to mitigate toxicity or terminate the
therapeutic effect after tumor clearance. We have
recently shown in a pre-clinical model that depletion of
CD19-CAR_EGFRt T cells after lymphoma eradication
reverses B-cell aplasia as the major long-term side effect
and adds another layer of safety to CD19-CAR T-cell
therapy (Paszkiewicz et al., 2016).
Regulatory considerations for clinical trial
approval
Currently, the main focus of clinical development of the
SB transposon/transposase system is on ex vivo gene
delivery into primary cells. Thus, from a regulatory point
of view, the actual investigational medicinal product
(IMP) administered to humans are the genetically modi-
fied cells, which in the European Union (EU) are classi-
fied as gene therapy medicinal product (GTMP) in most
cases. In the EU, GTMPs belong to the group of
advanced therapy medicinal products (ATMPs). Basic
guidance on the regulatory requirements for this type
of products regarding quality and non-clinical aspects,
as well as on clinical development is given in the
“Guideline on quality, non-clinical and clinical aspects of
medicinal products containing genetically modified
cells” (EMA/CAT/GTWP/671639/2008), which was
released in 2012. However, in this guideline only limited
information is provided on the new technologies for
genetic modification of cells, such as the transposon/
transposase system.
For genetically modified cells, both the cells to be
modified as well as the vector encoding the transposon
and the therapeutic gene are considered to be starting
materials, and need to be manufactured according to
the principles of GMP. However, in case of primary cell
donation, procurement and testing of the cells can be
performed outside of a GMP environment. The princi-
ples of testing quality parameters during manufacturing
and for release of the final product are, for the cellular
component, similar to most cell therapies, irrespective
whether the cells are genetically modified or not, but
may depend on the cell type employed.
One important aspect that is specific for transposon-
based genetic modification of cells is to monitor the
integration profile of the transposon and the number of
vector copies integrated into the host genome. As dis-
cussed above, genomic integration may have functional
consequences, and such impact on the genetic stability
of the cells and their proliferation and differentiation
capacity needs to be analyzed and documented. In add-
ition, potential toxic effects by the transposase need to
be taken into account. In many cases the potency of
such products is directly linked to the number or per-
centage of gene-modified cells as well as to the levels
of expression of the therapeutic sequence. It is import-
ant to determine these parameters already in early clin-
ical phases as release criteria for each batch. Increasing
clinical experience would then allow the development
of biological assays indicative for the functional activity
of the therapy and related to the clinical efficacy.
In contrast to classical integrating vectors such as
retro- or lentiviral vectors, which deliver and insert the
therapeutic sequence into the host genome in a “one-
shot” process, the transposon in theory is able to be
repeatedly excised and integrated at different loci in
case of persistent transposase activity. Therefore, a crit-
ical issue is the presence of the transposase at the time
of administration of the IMP. Delivery of the transposase
as protein might thus be preferable to delivery via
transposase-encoding mRNA or DNA; however, this will
most probably be at the expense of efficacy of the gen-
etic modification. Currently, transcriptionally regulated
transposase expression systems are under evaluation, to
allow for highly efficient delivery of the transposase
gene and concurrent switch-off of gene expression prior
to administration of the cell to the patient (Cocchiarella
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et al., 2016). In such a case, full function of the system
including control of leakage needs to be demonstrated
before clinical application.
As for all other gene modifying systems, the risk of
insertional oncogenesis due to semi-random genomic
integration is an important regulatory concern prior to
human use. Transposons integrate their payload, similar
to retro- and lentiviruses, in a more or less random fash-
ion bearing the risk of activating a proto-oncogene or
inactivating a tumor suppressor gene, as discussed
above. However, additional factors may contribute to
the risk of oncogenesis, such as the presence and
strength of transcriptional regulatory elements, the
therapeutic gene, the vector dose, the target cell popu-
lation, and the indication to be treated (Aiuti et al.,
2013b). Thus, the need and, if so, the extent of integra-
tion studies, genotoxicity and tumorigenicity studies
strongly depends on the above parameters employed
in context of the transposon/transposase delivery sys-
tem. The current clinical database available for retro- or
lentiviral vector-transduced T cells used in cancer
immunotherapy, for example, justifies that integration
studies for this type of therapy are omitted, taking into
account also the life-threatening nature of the disease
with poor treatment alternatives. For the transposon/
transposase system, clinical experience is more limited,
and thus a decision on the need for integration and/or
tumorigenicity studies is on a case-by-case basis, and
should follow a risk-based approach. In any case, use of
transient delivery of the transposase in the form of
mRNA or recombinant protein is preferred over transpo-
sase coding sequences in the form of DNA to limit
transposase activity to reduce the risk of insertional
mutagenesis.
Perspective: Sleeping Beauty – a possible new
gold standard for gene transfer!
The first clinical application of the SB system is currently
ongoing using autologous T cells gene-modified with
SB vectors carrying a CAR to render the T cells cytotoxic
specifically toward CD19-positive lymphoid tumors
(Huang et al., 2008; Kebriaei et al., 2016; Singh et al.,
2008). Lymphocytes represent a suitable initial platform
for testing new gene transfer systems, as T cells can be
genetically modified using viral and non-viral
approaches without apparent resulting genotoxicity.
The advantage of using the SB system for genetic modi-
fication includes i) the ease and reduced cost associated
with manufacturing of clinical-grade, plasmid-based
vectors compared with recombinant viral vectors, ii)
scalability: SB vectors can be manufactured in any
quantity, iii) easy quality control for clinical use, and iii)
indefinite storage with absolute fidelity.
A major hurdle in ex vivo delivery of the transposon
components into relevant primary cell types is the tox-
icity of contemporary transfection/electroporation pro-
tocols. In situations, where target cells are scarce and/or
culturing and expansion of the transfected cells is
impossible or cannot be solved without compromising
cell identity and grafting potential, cytotoxicity of the
transfection procedures is a serious issue that may
undermine clinical applications. However, recent experi-
mental data indicate that by employing transposon cas-
settes vectorized as MCs and by providing the
transposase in the form of mRNA cellular toxicity can be
reduced (Monjezi et al., 2016), thereby positioning clin-
ical applications with SB well within reach, at least in
the area of T cell engineering.
Alternatively, the development of hybrid vector sys-
tems combining the natural ability of viruses to traverse
cell mebranes with efficient genomic insertion medi-
ated by the SB system can be a promising strategy.
Indeed, components of the SB transposon have been
incorporated into integrase-defective lentiviral particles
that showed efficient gene transfer in a range of human
cell types and an insertion profile favorable to conven-
tional lentiviral vectors (Moldt et al., 2011; Staunstrup
et al., 2009; Vink et al., 2009). Hybrid adenovirus/SB vec-
tors (Boehme et al., 2016; Yant et al., 2002) have been
used to efficiently deliver SB transposon vectors
expressing FIX into the liver in a hemophilic dog model
(Hausl et al., 2010). Recently, a new approach was estab-
lished based on a hybrid adenovirus/SB vector targeted
to CD46, a receptor expressed on HSCs. The system has
been shown to yield up to 10% stable gene transfer in
HSCs following in vivo transduction, thereby alleviating
the need for myeloablation and transplantation (Richter
et al., 2016). Retroviral vectors disabled in generating a
cDNA copy of the retroviral vector have been shown to
deliver the SB transposase mRNA into target cells with
an impressive efficiency (Galla et al., 2011). Herpes sim-
plex virus vectors with a tropism to infect neural pro-
genitor cells have been used to target SB insertions in
the central nervous system in an in utero gene delivery
system in the mouse (Bowers et al., 2006; de Silva et al.,
2010). Finally, similar to adenovirus, baculoviral vectors
can efficiently transduce many cell types, but can only
provide transient expression in the absence of stable
genomic integration. Hybrid baculovirus/SB vectors
have been shown to confer prolonged transgene
expression in human cells both in vitro and in vivo in
intratumoral injections in xenograft mice (Luo et al.,
2012), as well as in vivo in the mouse eye (Turunen
et al., 2014). Note that, although these hybrid virus/SB
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transposon vectors may provide advantage from a tech-
nical point of view (non-toxic delivery of the SB vector
components into target cells), their application would
lose all the advantages of a fully non-viral system that
we outlined above.
Ex vivo modification of T cells is currently limited to a
small number of centers with the required infrastructure
and expertise in the logistics of cell isolation, activation,
gene transfer, expansion and cryopreservation steps. To
simplify procedures and widen applicability for clinical
therapies, automation of these procedures is being
developed. The CliniMACS ProdigyVR (Miltenyi Biotec,
Bergisch Gladbach, Germany) device delivers automated
cell processing in a closed GMP-compliant system, and
has recently been adapted for lentiviral transduction of
T cells (Mock et al., 2016). The advantage of the system is
that it can standardize the complete manufacturing pro-
cess of cellular products. Future generations of the sys-
tem adapted to non-viral vector delivery may advance
manufacturing of SB-engineered cellular products.
Alternative technologies for genetic engineering in
clinically relevant cell types are rapidly advancing.
Designer nucleases, including zinc finger nucleases
(ZFNs), transcription activator like effector nucleases
(TALENs) and clustered regularly interspaced short pal-
indromic repeat (CRISPR)/Cas nucleases are excellent
tools for genome engineering and gene editing
(Doudna & Charpentier, 2014). The common advantage
of these technologies is that they enable site-specific
engineering of the genome, thereby allowing introduc-
tion of facile and highly specific changes in the genetic
code. These technologies are making their way toward
therapeutic applications (Yu et al., 2016); for example,
site-specific gene addition at reasonable efficiencies has
recently been demonstrated by mRNA encoding ZFN
and a homology template delivered as AAV in both
HSCs (Wang et al., 2015) and T cells (Wang et al., 2016a).
One key difference that sets designer nucleases apart
from a transposon is that they are specialized and
highly active at cutting the genome at a specific
sequence, but transgene addition at the cut site is
dependent on double strand break repair mechanisms
of the cell. In contrast, transposons are gene integration
“machines” that evolved to insert themselves into the
genome; an attribute that forms the basis of applying
them for robust gene transfer.
Finally, the sequence “space” of the SB transposase
remains largely unexplored for hyperactive phenotypes.
Importantly, the crystal structure of SB100X’s catalytic
domain has recently been solved (Voigt et al., 2016).
The structure was highly informative with respect to
rationalizing the biochemical basis of hyperactivity of
already existing SB mutants, and can likely be used in
the future for structure-based design of next generation
SB transposases for therapeutic gene delivery.
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